The high risk of sensitisation does not justify the routine use of DSTs ( Level III evidence) A single pre- transplant DST is as effective as multiple DSTs. ( Level III evidence) The potential benefit of DST needs to be weighed against the risk of sensitisation ( approximately 30%) and infection. There is insufficient evidence on the use of DSTs to assist deletion of donor- specific antibodies pre- transplant to support their use.